ClinicalTrials.gg
CompletedNCT05242874Updated Oct 10, 2024

Anti-emetic Prophylaxis With or Without Dexamethasone

A Phase 3 interventional study of Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen and Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen in Chemotherapy-induced Nausea and Vomiting, sponsored by Henan Cancer Hospital. Completed at 2 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-10.

Sponsored by Henan Cancer Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Vomiting with a site in China — 22 open to participants now, 22 under way, 6 of them phase 3. Vomiting · China.

Enrollment
11th of 68
442 · median 150
Started
2022
with 8 others
Phase 3
21 of 73
6 open now
Registered
35th of 73
by date
Lead sponsor
2 of 73
Henan Cancer Hospital

Among the 73 studies in Vomiting with a site in China, this one is the 11th largest by enrollment of the 68 interventional ones that give a count, is one of 9 that started in 2022, is one of 21 in phase 3, and was the 35th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 98 are open to participants now.

Browse Vomiting studies →

Open to participants now

22 of the 73 studies in Vomiting with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 57 Vomiting studies recruiting now, 27 (47%) set no upper age limit and 24 (42%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Vomiting with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of a fosaprepitant, tropisetron, and olanzapine antiemetic regimen, with or without dexamethasone, in patients receiving highly emetogenic chemotherapy with epirubicin and cyclophosphamide.

Read the detailed description

Patients in this study were randomly assigned in a 1:1 ratio to one of two groups using an interactive response system with permuted blocks of four, stratified by age (\<55 vs. ≥55 years). They received either a three-drug antiemetic regimen with fosaprepitant, tropisetron, and olanzapine (triple group) or a four-drug regimen including fosaprepitant, tropisetron, olanzapine, and dexamethasone (quadruple group). All patients were hospitalized for approximately 120 hours post-chemotherapy, documenting emetic episodes, rescue medication use, and nausea ratings on a Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea, 3 = severe nausea) in a diary. Rescue therapy was available as needed. Clinical staff monitored adverse events every 24 hours using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Subjects who initiated treatment were followed up for endpoints, including complete response (CR), complete control (CC), total control (TC), quality of life, and safety assessments.

03

Conditions studied

  • Chemotherapy-induced Nausea and Vomiting

Keywords

  • Nausea
  • Vomiting
  • Glucocorticoids
  • Olanzapine
  • Tropisetron
  • Fosaprepitant
  • Signs and Symptoms, Digestive
  • Antiemetics
  • Physiological Effects of Drugs
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Breast cancer patients receiving their first anthracycline/cyclophosphamide-based HEC regimen (cyclophosphamide 600 mg/m², epirubicin 90-100 mg/m²); divided doses excluded.
  2. No prior chemotherapy.
  3. Aged 18-70 years.
  4. performance status 0 or 1.
  5. Adequate organ function: (including ≥1,500/mm3, WBC count≥3,000/mm3, count≥100,000/mm3, \< 2.5×the (ULN), ALT\< 2.5×ULN, \< 1.5×ULN, creatinine\< 1.5×ULN).
  6. No nausea or vomiting within 24 hours before registration.
  7. Negative pregnancy test within 7 days prior (women of ).
  8. No severe cognitive impairment.
  9. No to fosaprepitant, tropisetron, olanzapine, and dexamethasone.
  10. No significant cardiac issues: arrhythmia, recent heart failure, or myocardial infarction within 6 months.
  11. No symptomatic or carcinomatous meningitis.
  12. No diabetes requiring insulin or oral medication.
  13. No use of prohibited medications within 48 hours before registration or during treatment.
  14. obtained.

Exclusion criteria

Exclusion Criteria:

  1. History of allergic reactions to study drugs or their analogues.
  2. Nausea and vomiting requiring antiemetic treatment at registration.
  3. Pregnant or nursing women, those who may become pregnant, or those not planning to use .
  4. Mental illness or psychiatric symptoms interfering with daily activities, making study participation difficult.
  5. Diabetes treated with insulin/oral hypoglycemics or (NGSP) ≥ 6.5% or HbA1c (JDS) ≥ 6.1% at registration.
  6. Recent (within 6 months) unstable angina, myocardial infarction, cerebral hemorrhage, cerebral infarction, or active gastroduodenal ulcer.
  7. Convulsive disorders requiring anticonvulsants, ascites needing therapeutic puncture, or gastrointestinal obstruction.
  8. Inability to be hospitalized for up to 120 hours (Day 6) post-AC administration initiation.
  9. Any other conditions deemed inappropriate for study participation.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
442 participants (actual)

Study arms

  • Experimental
    Triple group

    A three-drug antiemetic regimen with fosaprepitant, tropisetron, and olanzapine (triple group)

    Drug: Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen

  • Active comparator
    Quadruple group

    A four-drug regimen including fosaprepitant, tropisetron, olanzapine, and dexamethasone (quadruple group)

    Drug: Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen

Interventions

  • DrugFosaprepitant, tropisetron, and olanzapine-based antiemetic regimen

    Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4.

    Also known as: Fosaprepitant+Tropisetron+Olanzapine

  • DrugFosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen

    Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.

    Also known as: Fosaprepitant+Tropisetron+Olanzapine+Dexamethasone

06

What researchers measure

Primary outcomes

  1. Complete response rate (CR) during overall (0-120 hours after the initiation of anthracycline/cyclophosphamide administration) phase.

    CR was determined by the absence of any retching or vomiting and the absence of any requirement for additional antiemetic treatment.

    Time frame: 0-120 hours after the initiation of anthracycline/cyclophosphamide administration

Secondary outcomes

  1. CR during the acute (0-24 hours after the initiation of anthracycline/cyclophosphamide administration) and delayed (24-120 hours after the initiation of anthracycline/cyclophosphamide administration) phase

    CR was determined by the absence of any retching or vomiting and the absence of any requirement for additional antiemetic treatment.

    Time frame: 0-24 hours and 24-120 hours after the initiation of anthracycline/cyclophosphamide administration

  2. Complete control rate (CC) during the acute, delayed, and overall phase

    CC is defined as a condition in which a patient does not report more than mild nausea (0 or 1 on a 4-grade categorical scale) (0 = no nausea, 1 = mild nausea, 2 = moderate nausea, 3 = severe nausea).

    Time frame: Day 1 to day 5 after the initiation of anthracycline/cyclophosphamide administration

  3. Total control rate (TC) during the acute, delayed, and overall phases

    TC is defined as a condition in which a patient does not report any nausea (0 on a 4-grade categorical scale) (0 = no nausea, 1 = mild nausea, 2 = moderate nausea, 3 = severe nausea).

    Time frame: Day 1 to day 5 after the initiation of anthracycline/cyclophosphamide administration

  4. Safety outcomes

    Adverse event incidence rate

    Time frame: Day 1 to day 5 after the initiation of anthracycline/cyclophosphamide administration

  5. Quality of life based on Functional Living Index-Emesis (FLIE) assessment

    Quality of life based on Functional Living Index-Emesis (FLIE) assessment in the overall phase (0-120 h).

    Time frame: 0-120 hours after the initiation of anthracycline/cyclophosphamide administration

  6. Exploratory endpoints-The time to the treatment failure

    The time to the treatment failure (time to first emetic episode or time to first use of rescue medication, whichever occurred first).

    Time frame: 0-120 hours after the initiation of anthracycline/cyclophosphamide administration

07

Study locations

2 sites
  • Henan cacer hospital
    Henan, Henan 450008, China
  • Henan cancer hospital
    Zhengzhou, Henan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2023, 18 months.

Of 37 non-industry phase 3 interventional studies under Vomiting, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 18 months is below that.

Counting every sponsor, half of 56 studies reached it within 21 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Feb 16, 2022
StartActual
Feb 1, 2022
Primary completionActual
Aug 15, 2023
CompletionActual
Aug 15, 2023
Last update
Oct 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05242874
Responsible party
Zhenzhen Liu (Director, Head of Breast Oncology, Henan Cancer Hospital) — Principal investigator
First posted
Feb 16, 2022
Start date
Feb 1, 2022
Primary completion
Aug 15, 2023
Completion
Aug 15, 2023
Last update
Oct 10, 2024

Study contacts

Zhenzhen Liu
principal investigator · Henan Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion